Vaccination Guidelines for Cancer Patients (ASCO Guidelines)
Evidence-based vaccination protocols before, during, and after cancer treatment for active patients and survivors
ASCO Clinical Guidance & In-Person Care Notice:
This information is educational and based on ASCO (American Society of Clinical Oncology) guidelines. It does not replace a consultation with your oncologist. Vaccination plans must be tailored to your specific cancer diagnosis, treatment cycle, and immune status. All clinical evaluations and vaccination history reviews are conducted strictly in-person at MB Hospital Campus, Udaipur — no teleconsultation is offered.
Assessment, Planning & Timing During Treatment
Coordinating immunization prior to or during chemotherapy and immunotherapy
- 1Review your full vaccination history with your oncologist at the time of cancer diagnosis.
- 2Aim to complete recommended vaccines 2–4 weeks before starting chemotherapy, radiation, or immunosuppressive therapy whenever possible.
- 3Most non-live vaccines are safe to administer during or after chemotherapy, immunotherapy, radiation, or surgery.
- 1Coordinate vaccine administration closely with your oncology treatment team.
- 2Avoid vaccination during periods of profound neutropenia or severe immunosuppression unless specifically advised by your doctor.
- 3Non-live (inactivated/recombinant) vaccines generally do not interfere with the effectiveness of cancer treatments.
Recommended Vaccines for Cancer Patients
Inactivated and recombinant vaccines categorized by priority and seasonality
Seasonal Respiratory Vaccines
Inactivated flu shot every year, regardless of age. High-dose versions may be preferred after certain bone marrow or stem cell transplants.
Stay up to date with the latest updated formulations as recommended for immunocompromised individuals.
One dose recommended for cancer patients aged 60 years and older after consultation with provider.
Core Protective Vaccines
One dose of PCV20 or a combination of PCV15 followed by PPSV23 for adults 19 years and older with cancer.
Two-dose series of the recombinant non-live Shingrix vaccine for cancer patients 19 years and older.
One initial dose of Tdap if not previously received, with Td or Tdap boosters every 10 years.
Complete the 2-dose or 3-dose vaccination series for ages 19–59 years or older adults with risk factors.
Other Considered Vaccines
3-dose series for patients ages 19–26 years; shared decision-making for ages 27–45 years.
Use inactivated travel vaccine options and follow destination guidance. Live travel vaccines must be strictly avoided during treatment.
Special Situations in Cancer Care
Revaccination protocols after Bone Marrow Transplant, CAR-T, or B-Cell depleting therapy
- Begin a full revaccination schedule 6–12 months after transplant to restore lost immune memory.
- Inactivated Influenza, COVID-19, and Pneumococcal vaccines may start as early as 3 months post-transplant.
- Delay all live vaccines for at least 2 years post-transplant or until completely off immunosuppressive medications and graft-versus-host disease (GVHD) therapy.
- Influenza and COVID-19 vaccines: Administer no sooner than 3 months following therapy.
- Most other non-live vaccines: Typically wait 6 months or longer until B-cell recovery occurs.
- Revaccination series for COVID-19 may be needed 6 months after completing B-cell-depleting antibody therapy (e.g., rituximab).
Vaccines to Avoid & Caregiver Ring Protection
Contraindicated live vaccines during active immunosuppression and family shielding steps
Live attenuated vaccines contain weakened live viruses that can cause severe viral disease in patients with suppressed immune systems.
- Nasal Spray Flu Vaccine (LAIV)
- MMR (Measles, Mumps, Rubella)
- Varicella (Chickenpox)
- Yellow Fever & Oral Typhoid Vaccines
- Ensure family members, household contacts, and caregivers are fully vaccinated (ring vaccination strategy).
- Close contacts can safely receive non-live vaccines and most live vaccines (except oral polio or live nasal flu spray).
- Long-term cancer survivors with ongoing immune challenges should continue non-live booster vaccines as recommended by their oncologist.
Key Immunological & Health Benefits
Reduces Infection Risk
Substantially lowers the risk of severe bacterial and viral infections that are far more dangerous during cancer therapy.
Prevents Treatment Delays
Preventing serious respiratory or systemic illnesses helps keep chemotherapy and radiation schedules on track without interruption.
Immunological Shielding
Although immune response to vaccines may be reduced during therapy, partial antibody protection significantly improves clinical outcomes and recovery.
Frequently Asked Questions About Patient Vaccination
QCan cancer patients safely receive vaccines during chemotherapy?
Most non-live (inactivated or recombinant) vaccines are safe during or after chemotherapy. However, live vaccines are strictly avoided during active treatment due to reduced immune function.
QWhen is the best time to get vaccinated relative to cancer treatment?
Ideally, recommended vaccines should be administered 2 to 4 weeks prior to starting chemotherapy or immunosuppressive treatment to allow the immune system to build antibodies.
QWhy should family members and caregivers also get vaccinated?
Ring vaccination protects immunocompromised patients by creating a shield around them. Family members and household contacts should stay up to date on annual flu shots and COVID-19 boosters.
QIs revaccination required after a bone marrow or stem cell transplant?
Yes. Stem cell transplant recipients lose previously acquired antibody immunity and require a full revaccination series starting 6 to 12 months after transplant under medical supervision.
In-Person Consultation Locations
Vaccination history review, pre-chemotherapy immunization timing, and post-transplant revaccination guidance are conducted in-person at MB Hospital Campus, RNT Medical College, Udaipur. Patients traveling from Rajsamand, Chittorgarh, Dungarpur, Banswara, and nearby districts can consult Dr. Narendra Rathore in-person:
Schedule Your OPD Consultation
All oncology consultations, scan reviews, and treatment planning with Dr. Narendra Rathore are conducted strictly in-person at MB Hospital campus, Udaipur.
- Original Biopsy & Histopathology Reports
- CT / MRI / PET Scan Films & DICOM CDs
- Prior Doctor Prescriptions & Chemotherapy Records
- Patient Photo ID & Scheme Card (RGHS / Chiranjeevi)